Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Results of a multisite randomized trial of Bright IDEAS-Young Adults: Efficacy of problem-solving skills training on distress and health-related quality of life.

Katie Devine, Marie Barnett, Kristine A. Donovan et al. Jun 01, 2025 pp. 12005-12005 10.1200/jco.2025.43.16_suppl.12005

12005 Background: Young adults (YAs) diagnosed with cancer between the ages of 18 and 39 face unique psychosocial challenges and are at risk of experienci...

Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study.

Yinan Shen, Xingmei Liang, Tian Fang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14605

e14605 Background: Advanced hepatocellular carcinoma has a rapid progression and poor prognosis. Although drugs have been approved as standard therapies,...

HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.

Min Lai, Liying Zhao, Li Guoxin et al. Jun 01, 2025 pp. 4025-4025 10.1200/jco.2025.43.16_suppl.4025

4025 Background: The human epidermal growth factor receptor 2 (HER2) expression undergoes changes during the treatment of gastric cancer. This study aims...

Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients (pts) with NTRK fusion-positive (NTRK+) solid tumors.

Yizhuo Zhang, Huanmin Wang, Yeming Wu et al. Jun 01, 2025 pp. 10048-10048 10.1200/jco.2025.43.16_suppl.10048

10048 Background: NTRK gene fusions are significant oncogenic drivers in pediatric tumors (e.g. infantile fibrosarcoma). Zurletrectinib is a highly select...

Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.

Elisa Fontana, Aakash Desai, Nuria Kotecki et al. Jun 01, 2025 pp. 8611-8611 10.1200/jco.2025.43.16_suppl.8611

8611 Background: PDL1V is an investigational antibody-drug conjugate that delivers the cytotoxic agent monomethyl auristatin E to cells expressing program...

ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.

Jiujie Cui, Wei Li, Jingyu Cao et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4228

TPS4228 Background: Metastatic pancreatic cancer (mPC) remains one of the most challenging malignancies to treat, with limited effective therapeutic optio...

Enhancing personalized prognosis in appendiceal (AC) and cecal adenocarcinoma (CA) with machine learning.

Abdalwahab M.Z.M. Alenezy, Sakhr Alshwayyat, Tala Abdulsalam Alshwayyat et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16484

e16484 Background: AA and CA are rare gastrointestinal neoplasms (2% and 1.2%, respectively) that are understudied and difficult to diagnose. We aimed to...

Impact of metformin on the efficacy of immune checkpoint inhibitors in metastatic melanoma: A large-scale retrospective analysis.

Ammad Naeem, Muhammad Mujtaba Bhinder, Mohammad Khudayar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21548

e21548 Background: Metformin, widely used for type 2 diabetes mellitus (T2DM), has been hypothesized to influence the tumor microenvironment and potential...

Assessment of ovarian function suppression (OFS)-containing adjuvant endocrine therapy in premenopausal women by Breast Cancer Index.

Ruth O'Regan, Yue Ren, Yi Zhang et al. Jun 01, 2025 pp. 557-557 10.1200/jco.2025.43.16_suppl.557

557 Background: Breast Cancer Index (BCI) previously identified that premenopausal patients with HOXB13/IL17BR ratio (H/I)-Low tum...

Engineered AAV vectors with dual tumor-specific promoters for safer and more effective cancer therapy.

Can Song, Shengjiang Tan, Hongyu Li et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15112

e15112 Background: Solid tumors remain a significant challenge in oncology due to recurrence, side effects, and resistance...

Prognostic impact of preoperative imaging-detected extranodal extension in head and neck squamous cell carcinoma treated with postoperative chemoradiotherapy.

Yuta Hoshi, Hirofumi Kuno, Shingo Sakashita et al. Jun 01, 2025 pp. 6063-6063 10.1200/jco.2025.43.16_suppl.6063

6063 Background: In 2024, the Head and Neck Cancer International Group (HNCIG) newly defined imaging-detected and pathological extranodal extension (iENE/...

Molecular subtyping and insights into sarcoma biology and prognosis.

Aleksei Shevkoplias, Angelina Khachatryan, Vladimir Kushnarev et al. Jun 01, 2025 pp. 11536-11536 10.1200/jco.2025.43.16_suppl.11536

11536 Background: Sarcomas represent a diverse group of mesenchymal malignancies, with over 200 subtypes recognized by the WHO. This heterogeneity, combin...

Effect of HLA class I expression on the tumor immune microenvironment and prognosis in prostate cancer.

Pornlada Likasitwatanakul, Carissa Besonen, Negar Sadeghipour et al. Jun 01, 2025 pp. 5044-5044 10.1200/jco.2025.43.16_suppl.5044

5044 Background: Human leukocyte antigen (HLA) class I comprises a family of peptide-binding proteins that regulate T-cell interactions. Here, we examined...

Evaluation of eligibility criteria in randomized controlled trials for chronic lymphocytic leukemia over 15 years.

Laura Budvytyte, Nadia Islam, Talal Hilal Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23024

e23024 Background: Efforts to address disparities in clinical trial participation have increased over the past 30 years. Strict eligibility criteria in ph...

Tolerance to CD4/6 inhibitor therapy as first line therapy among ER+ patients with metastatic breast cancer.

Elham Nasrollahi, Ali Sanjari Moghaddam, Daria Chelysheva et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13020

e13020 Background: CDK4/6 inhibitors are crucial in managing hormone receptor-positive, HER2-negative metastatic breast cancer (MBC), significantly improv...

Efficacy of envafolimab combined with capecitabine and lenvatinib as postoperative adjuvant therapy for radical resected cholangiocarcinoma with high-risk recurrence factors: A phase II single-center prospective study.

Mingyu Chen, Yitong Tian, Tianao Xie et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16289

e16289 Background: Surgery remains the cornerstone of curative treatment for cholangiocarcinoma. However, recurrence rates remain high (60-70%) even after...

A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL).

Swaminathan P. Iyer, Steven M. Horwitz, Salvia Jain et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps7086

TPS7086 Background: R/R TCL presents an unmet clinical need with limited treatment options and 3-year survival < 20%. MB-105 is an autologous CD5-targe...

Feasibility and efficacy of oral 5-FU in combination with pembrolizumab and cisplatin as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma: A prospective observational study.

Jason Chia-Hsun Hsieh, Pei-Hung Chang, Meng-Che Hsieh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18009

e18009 Background: This study addresses the need for alternative treatments in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pati...

Anti-tumor activity of CoREST inhibitor, JBI-802 (dual epigenetic modifier of LSD1/HDAC6): An opportunity to treat essential thrombocythemia and MPN/MDS patients with thrombocytosis in ongoing phase 1/2 clinical trial.

Melda S. Dolan, Sridharan Rajagopal, Abhijit B. et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps6589

TPS6589 Background: Lysine specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6) are epigenetic proteins associated with several diseases, inclu...

TOPS (Trainees in Oncology Programs): A professional development curriculum for oncology fellows.

Ashlee Candelaria, Teresa Rutledge, Bridget N. Fahy et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21016

e21016 Background: Professional development is an integral component of successful oncology training; oncology fellows across all disciplines need guidanc...

Association between frailty and healthcare resource utilization in older adults with pancreatic cancer: A retrospective cohort study.

Marina Sehovic, David Meawad, Mohamed E. Ali et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16404

e16404 Background: Frailty is a critical determinant of health outcomes in older adults and may influence the management and prognosis of pancreatic cance...

Does frailty modulate the predictive value of performance status in older adults with cancer?

Daniela Patino-Hernandez, Mario Ulises Pérez-Zepeda Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13844

e13844 Background: Cancer treatments are not a one-size-fits-all approach, and even when age is a well-known risk factor for developing malignant neoplasm...

Denosumab monotherapy versus bisphosphonate switching in breast cancer bone metastases: A real-world cohort study on skeletal events and safety.

Kuikui Jiang, Fei Xu Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13166

e13166 Background: In real-world clinical practice, the administration of denosumab frequently deviates from standardized clinical trial protocols. Common...

Outcomes from targeted axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer in a safety-net medical center.

Stephen Francis Sener, Danielle Brabender, Alexa Griffiths et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12608

e12608 Background: Prior data from this Center demonstrated that axillary node recurrence was uncommon after targeted axillary dissection for patients who...

Creation of the ideal health care pathway for integrating ctDNA testing into clinical practice through multi-stakeholder engagement.

Lidewij Vat, Brian Goodman, Eleonora Barile et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23032

e23032 Background: The GUIding multi-moDal thErapies against Minimal Residual Disease by liquid biopsies (GUIDE.MRD) consortium is a precision oncology pu...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page